We investigated various combination treatment regimens employing nilotinib with established chemotherapeutic agents (daunorubicin, mitoxantrone, etoposide and cytarabine) in imatinib-sensitive and -resistant BCR-ABLpositive cells. Mitoxantrone or cytarabine showed synergism (CI < 1) in combination with nilotinib in imatinib-sensitive LAMA84 cells, whereas in imatinib-resistant LAMA84-R cells synergistic eVects could be assessed for daunorubicin, mitoxantrone and etoposide when combined with nilotinib. In both imatinib-sensitive and -resistant K562 cells daunorubicin, mitoxantrone and etoposide demonstrated synergism in combination with nilotinib. Moreover, both daunorubicin and mitoxantrone led to synergistic antiproliferative eVects when combined with nilotinib in imatinib-resistant Ba/F3 cells carrying point mutations in the ABL TK domain (E255K, E255V and T315I). Annexin V/propidium iodide staining revealed a signiWcant enhancement of nilotinib-induced apoptosis in imatinib-resistant Ba/F3T315I and LAMA84-R cells upon combination with daunorubicin and mitoxantrone, respectively. Our results demonstrate the eYcacy of combination treatment regimens employing nilotinib and established chemotherapeutic agents in improving antileukemic eVects in imatinib-sensitive and imatinib-resistant cells. This may be the foundation for further study on the potential of the applied combinations in a clinical setting.
Introduction
Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disease characterized by the chromosomal translocation t(9;22)(q34;q11) known as the Philadelphia (Ph 1 ) chromosome [1] [2] [3] . On the molecular level this aberration leads to the expression of the BCR-ABL fusion protooncogene with transforming potency due to a deregulated ABL tyrosine kinase (TK) activity [3, 4] . The development and application of imatinib targeting the ABL TK has revolutionized the treatment of CML making imatinib the therapeutic gold standard for this disease [5, 6] . However, resistance to imatinib can evolve. Up to now various molecular mechanisms of resistance have been described, most notably mutations in the BCR-ABL TK domain and an increased BCR-ABL activity resulting from gene ampliWcation, up-regulation, or multiple Ph chromosomes [7] [8] [9] [10] . Consequently, the eVort to overcome imatinib resistance within current treatment strategies lead to the development of second-generation TK inhibitors (TKI).
Nilotinib is a potent, second-generation aminopyrimidine ATP-competitive inhibitor of BCR-ABL. It has been shown not only to be at least 20-fold more potent than imatinib in killing cells with non-mutated BCR-ABL in vitro, but also to inhibit the activity of the majority of mutant forms of BCR-ABL occurring in imatinib-resistant patients [11, 12] . Furthermore, recent clinical trials found nilotinib eVective and safe in patients with CML post-imatinib failure or intolerance [13, 14] . However, the eYcacy of nilotinib and other newer TK inhibitors is best in the chronic phase of CML and decreases with disease evolution to further stages. In particular, the blast crisis remains a serious clinical challenge [15, 16] . With either conventional intensive chemotherapy or the newer targeted therapies applied as single treatment, long-term survival in myeloid blast crisis is rare reaching a plateau below 10% if the patients are not oVered subsequent allogeneic stem cell transplantation upon achievement of response. On the other hand, an induction therapy leading to remission of blast crisis or to restoration of chronic phase was shown to be associated with improved outcome in patients receiving an allogeneic transplant [17] .
A number of preclinical studies by several investigators including our group could comprehensively show that combination treatment regimens, employing a TK inhibitor (imatinib) and substances with a diVering mode of action, lead to synergistic antiproliferative eVects presenting a feasible strategy to increase the antileukemic eYcacy and to circumvent imatinib resistance [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . In order to elucidate whether these observations can be translated to nilotinib, in the present study, we investigated several combinations applying nilotinib and established chemotherapeutic agents (daunorubicin, mitoxantrone, etoposide and cytarabine) in diVerent imatinib-sensitive and in particular imatinib-resistant BCR-ABL-positive leukemia cell lines.
Materials and methods
Cell lines and culture conditions K562 and LAMA84 cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) and were all sensitive to submicromolar concentrations of imatinib [21, 22] . The imatinibresistant cell lines LAMA84-R and K562-R were provided by Professor Junia Melo (London, UK) and were characterized in detail previously [21] . BCR-ABL-positive wild-type (wt) Ba/F3 wt cells expressing p185 BCR-ABL and the corresponding imatinib-resistant lines carrying mutations in the ABL TK domain (E255K, E255V and T315I) were established in the lab of Professor Justus Duyster (Munich, Germany) [28] .
All cells were grown in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine and penicillin/streptomycin (Invitrogen, Karlsruhe, Germany) at standard conditions (37°C, fully humidiWed atmosphere of 95% air and 5% CO2). In addition, LAMA84-R and K562-R cells were cultured in medium containing 1 M imatinib.
Drugs
Nilotinib was kindly provided by Novartis Pharma (Basel, Switzerland). Daunorubicin (DNR; Sigma, Steinheim, Germany), mitoxantrone (Sigma), etoposide (Bristol Arzneimittel, Munich) and cytarabine (Ara-C; Cell Pharm, Hannover, Germany) were purchased from the manufacturers. Nilotinib was initially dissolved in sterile 10% dimethyl sulfoxide solution (DMSO; Merck, Darmstadt, Germany). Other applied cytostatic drugs were dissolved in phosphate-buVered saline (Dulbecco's PBS; Invitrogen). Stock solutions at a concentration of 10 mM of each drug were prepared and stored at ¡20°C until use. For experiments, serial working dilutions were prepared.
Cell proliferation assay and analysis of drug eVects and interactions MTT assays were used for the assessment of cell proliferation with minor modiWcations as described previously [18, 21] . After 48 h of incubation with tested drugs, means of four replicate wells for each drug dilution and the control (cells grown in absence of the drug) were used to calculate the extent of relative cell proliferation and growth inhibition (deWned as fraction aVected (Fa) [18] ). Each cell line was treated with Wve increasing concentrations (doubling with each increment) of nilotinib and chemotherapeutic drug alone or their combination, respectively. Since nilotinib, in contrast to the other agents, was dissolved in 10% DMSO the serial drug dilutions and controls were prepared to Wnally achieve 0.05% DMSO in all wells (control, single agent and drug combinations; total volume 100 l). At this concentration no antiproliferative eVects of the applied DMSO solution could be observed in the investigated cell lines (data not shown).
Dose-eVect relationships and drug interactions upon combination of nilotinib and established drugs were analyzed according to the median-eVect method of Chou and Talalay [29] employing the CalcuSyn Software (Biosoft, Cambridge, UK). For single-agent treatment, mean IC50 values for each drug and cell line were calculated; for combinations mean combination index (CI) values based on equitoxic drug ratios were assessed with CI < 1, CI = 1 or CI > 1 representing synergistic, additive or antagonistic eVects of the substances, respectively, and combination data were depicted as CI versus Fa plots [18, 20] . In cell lines where no antiproliferative activity upon single-agent treatment was assessable, an analysis in terms of sensitization (potentiation) or inhibition of nilotinib activity was performed instead with relative IC50 > 1 indicating inhibition and relative IC50 < 1 indicating potentiation of nilotinib activity, respectively (for details see Topaly et al. [20] and Radujkovic et al. [22] ).
Apoptosis assay Assessment of apoptosis rates was done by annexin V/propidium iodide (PI) staining using the annexin V-FITC Kit (Immunotech, Marseille, France) 48 h after start of incubation as described previously [21, 22] . Data collection and analysis were performed with a FACScalibur Xow cytometer (Becton-Dickinson, Heidelberg, Germany) applying the CellQuest Software (Becton-Dickinson).
Statistics
Three to Wve independent experiments were performed and the results were depicted as mean value § standard deviation (SD). Statistical signiWcant diVerences of the data were calculated using the Student t test with signiWcance levels of p < 0.05 and p < 0.01.
Results

Single-agent treatment
Imatinib-sensitive LAMA84 and K562 cells were all sensitive to nanomolar concentrations of single-agent nilotinib (Table 1 ). In the imatinib-resistant counterparts LAMA84-R and K562-R substantially higher nilotinib concentrations for corresponding antiproliferative eVects were required. Imatinib-resistant K562-R cells displayed a remarkable resistance towards nilotinib with an IC50 value of 21,972 nM, i.e., approximately 600-fold higher than in the respective imatinib-sensitive K562 cells (34 nM); in the LAMA84-R line the IC50 value (124 nM) was 10-fold higher as compared to the parental line (11 nM). In imatinib-resistant Ba/F3 cells exhibiting point mutations in the BCR-ABL TK domain Ba/F3 E255K , Ba/F3 E255V and Ba/F3 T315I , the IC50 values of nilotinib were 365, 791 and 23,582 nM, respectively, i.e., about 16-, 34-and 1,000-fold higher than in the corresponding parental imatinib-sensitive Ba/F3 wt cell line (Table 1) .
Daunorubicin, mitoxantrone and etoposide displayed a concentration-dependent inhibition of proliferation after a 48-h treatment. Both intercalating drugs, the anthracycline daunorubicin and the anthracendione mitoxantrone, showed similar antiproliferative eVects in LAMA84 cells (Table 1) . In imatinib-resistant LAMA84-R cells considerably higher concentrations of both agents were necessary for growth inhibition as compared to the imatinib-sensitive LAMA84 line with mitoxantrone and daunorubicin IC50 values being increased by 10-and 20-fold, respectively, implying crossresistance towards both compounds (Table 1) . Regarding imatinib sensitivity, no signiWcant diVerences in the cytotoxicity of the substances could be observed in K562 cells. The activity of etoposide was substantially higher in the LAMA84 cells as compared to K562 with both imatinibresistant cell lines (LAMA84-R and K562-R) showing a reduced sensitivity (not signiWcant) towards etoposide (Table 1) . For cytarabine, only in imatinib-sensitive LAMA84 cells an IC50 value of 175 nM was calculable; in LAMA84-R cells and in the K562 pair no cytarabine activity could be detected. Daunorubicin displayed similar eVects on the growth of all investigated Ba/F3 lines; the same applies to mitoxantrone (Table 1) .
Combination treatment
In the imatinib-sensitive LAMA84 cell line combination treatment with nilotinib plus daunorubicin and nilotinib plus etoposide led to antagonistic (CI > 1; Fig. 1a) and » 1; Fig. 1e ) eVects, respectively. In contrast, the combinations employing mitoxantrone and cytarabine were both clearly synergistic denoted by CI values < 1 above the growth inhibition level >60% (Fa > 0.6) (Fig. 1c,  g ). Combination treatment of imatinib-resistant LAMA84-R cells resulted in enhanced antiproliferative eVects for every regimen. Analysis of combined eVects revealed synergism with CI values of 0.36 § 0.35, 0.59 § 0.24 and 0.91 § 0.07 for nilotinib plus daunorubicin, nilotinib plus mitoxantrone and nilotinib plus etoposide, respectively, at the 60% growth inhibition level (Fa = 0.6) (Fig. 1b, d, f) . Since cytarabine was inactive in LAMA84-R cells (Table 1) , the median-eVect method was not applicable for investigating combination eVects. However, non-cytotoxic doses of cytarabine (¸1,250 nM) led to a signiWcant reduction of nilotinib IC50 values (relative IC50 < 1) signifying potentiation of nilotinib activity (Fig. 1h) .
In imatinib-sensitive K562 cells daunorubicin and mitoxantrone showed synergistic eVects when combined with nilotinib at Fa¸0.4 and Fa > 0.3, respectively, (Fig. 2a, c) ; nilotinib plus etoposide acted synergistically at Fa < 0.8 (Fig. 2e) . In the imatinib-resistant K562-R line, combination treatment employing daunorubicin and etoposide displayed synergism (Fig. 2b, f) , whereas the combination nilotinib plus mitoxantrone was at best additive at Fa = 0.6 (Fig. 2d) . In both imatinib-sensitive and -resistant K562 cells no signiWcant potentiation of nilotinib activity could be observed by cytarabine (Fig. 2g, h) .
Combination treatment of imatinib-sensitive Ba/F3 wt cells with nilotinib plus daunorubicin and nilotinib plus mitoxantrone resulted in improved antiproliferative eVects as compared to the respective monotherapies with CI values indicating synergism above aVected fractions ¸0. 45 and Fa > 0.3, respectively (Fig. 3a, b) . Depending on the (Fig. 3c, e,  g ). For the combination nilotinib plus mitoxantrone, synergistic eVects were discernible with CI values < 1 above Fa > 0.7 in Ba/F3 E255K and above Fa¸0.2 in both Ba/ F3 E255V and Ba/F3 T315I cells (Fig. 3d, f, h ).
Induction of apoptosis
Monotherapy of the imatinib-resistant cell lines K562-R and LAMA84-R with low-dose nilotinib, daunorubicin or mitoxantrone increased the early apoptotic cell fractions (annexin V+/PI¡ cells) as compared to untreated controls. For 1,000 nM daunorubicin this eVect was more obvious with apoptotic fractions of 18% (K562-R) and 15% (LAMA84-R) as compared to nilotinib-(13 and 11%) and mitoxantrone-induced apoptosis (10% and 8%) in the respective lines. Compared to the corresponding monotherapies, drug combinations led to enhanced apoptosis levels (16-23%) with a signiWcant increase for nilotinib plus mitoxantrone in the LAMA84-R cell line (Fig. 4a) .
In the investigated imatinib-resistant Ba/F3 E255K and Ba/F3 T315I cells, respectively, only a marginal increase in the proportion of apoptotic cells upon administration of low-dose single-agent nilotinib (9 and 4%), daunorubicin (6% for both lines) and mitoxantrone (5 and 6%) could be observed as compared to untreated controls (4 and 3%; Fig. 4b ). Cotreatment of Ba/F3 E255K cells increased the early apoptotic cell fractions for both combinations (34% for nilotinib plus daunorubicin and 21% for nilotinib plus mitoxantrone). However, only in the Ba/F3 T315I cell line a signiWcant enhancement of apoptosis could be observed after treatment with the combination nilotinib plus daunorubicin versus monotherapy (Fig. 4b) .
Discussion
Our preclinical studies with combinations of imatinib and classic chemotherapeutic drugs demonstrated signiWcant synergistic action that translated in a better eYcacy in a clinical setting in myeloid blast crisis of CML [30] . To present, the majority of patients who progress to a blast crisis of CML have been pre-exposed to imatinib treatment at earlier disease stages and harbor a cell clone resistant to this drug. Several studies demonstrated that BCR-ABL signaling remains one of the principal mechanisms of disease pathogenesis in imatinib resistance. In cases of BCR-ABL TK mutations that confer imatinib resistance or in cases of up-regulated TK activity as compared to wild-type BCR-ABL, the newer more potent ABL kinase inhibitors are the rational treatment following imatinib failure.
However, in the course of disease evolution additional pathophysiological mechanisms may gain an increasing inXuence on cell proliferation, thus diminishing the eYcacy of single-agent TK inhibitors in blast crisis. The logical action to overcome drug resistance is the use of drug combinations with diVerent mechanisms of action. In the present study we investigated the eVects of classical chemotherapeutic drugs cytarabine, daunorubicin, etoposide, and mitoxantrone that are typically used in the treatment of acute leukemia. The drugs were used as single agents and as combination partners for nilotinib in imatinib-sensitive CML cells and in BCR-ABL-positive leukemia cells with deWned BCR-ABL TK mutations or other mechanisms of imatinib resistance.
In our previous published reports the eVects of imatinib treatment as a single agent and in combination with various compounds were studied extensively both in imatinib-sensitive and -resistant cells [18, 19, 21, 22] . Compared to imatinib treatment, the single-agent nilotinib showed an improved eYcacy in the investigated imatinib-sensitive cell lines, reXected by IC50 values in the nanomolar range (Table 1 ). In the imatinib-resistant LAMA84-R cell line nilotinib was also more eVective than imatinib underlining nilotinib's high potency [11, 12, 21] (Table 1) . Only the K562-R cell line, in which several diVerent resistance mechanisms are probably involved [7, 21, 31] showed a high resistance to both imatinib and nilotinib (IC50 values > 20,000 nM) ( Table 1) . With the exception of Ba/ F3 T315I , single-agent nilotinib was also active in the highly imatinib-resistant Ba/F3 E255K and Ba/F3 E255V cell lines, which is consistent with previous Wndings [11, 28] . Monotherapy with established chemotherapeutic agents resulted in variable antiproliferative eVects in the investigated cell lines. Interestingly, in both the K562 and LAMA84 pair higher concentrations of the applied intercalating drugs and etoposide were required for growth inhibition of the imatinib-resistant cells implying cross-resistance (Table 1) . Since daunorubicin, etoposide and mitoxantrone are substrates for the P-glycoprotein (Pgp) mediated drug eZux [32] [33] [34] , the known increased Pgp activity of these imatinib-resistant cell lines is one possible explanation [7, 21] . Cytarabine which displayed no antiproliferative eVects in the tested dose range in imatinib-resistant LAMA84-R and K562-R cells (Table 1) , however, has not been demonstrated to be a Pgp substrate [35] . Combination therapy employing nilotinib and classical chemotherapeutic drugs led to improved antileukemic eVects. In imatinib-resistant LAMA84-R cells these eVects resulted either from synergism (CI values < 1) or potentiation of nilotinib activity (Fig. 1) . In the imatinib-resistant K562-R cells, synergistic interactions could be observed to a lesser extent as compared to the imatinib-sensitive counterpart (Fig. 2) . In addition, the applied drug combinations acted synergistically also in Ba/F3 cells expressing deWned imatinib-resistant BCR-ABL mutants. However, in T315I carrying cells, conferring complete resistance to imatinib [11] , high doses of nilotinib were required to assess the synergistic interaction (>25,000 nM) limiting the clinical signiWcance (Fig. 3) .
The antiproliferative eVects of nilotinib are associated with induction of apoptosis [11, 36] . In our study, we investigated the pro-apoptotic eVects in imatinib-resistant cells. Since clinically isolated BCR-ABL kinase domain mutants show a varying incidence and resistance to imatinib [6, 11, 37] , we gave preference to the imatinib-resistant Ba/F3 T315I and Ba/F3 E255K cell lines harboring the more common BCR-ABL mutants with diVerent levels of imatinib resistance in our experiments. Regarding combination treatment, the apoptosis results in Fig. 4 appear to be inconsistent with the synergistic eVects observed in the cell proliferation assays (Figs. 1, 2, 3) . In our experiments, the extent of apoptosis was deWned as the proportion of early apoptotic cells (annexin V+/PI¡) which in contrast to the MTT assays shows no direct correlation to the viable cell number [38] . The corresponding fractions of dead (necrotic) cells (annexin V+/PI+) were considerably higher and displayed a stronger correlation to the cell proliferation experiments (data not shown). In our experiments, a signiWcant increase in the number of early apoptotic cells as compared to the respective monotherapies could only be observed in imatinib-resistant Ba/F3 T315I and LAMA84-R cells for the combinations nilotinib plus daunorubicin and nilotinib plus mitoxantrone, respectively, signifying the potential of the applied intercalating drugs to enhance nilotinib-induced apoptosis (Fig. 4) .
The underlying molecular mechanisms of the synergistic antiproliferative and pro-apoptotic eVects of tyrosine kinase inhibitors in combination with classic antineoplastic agents are poorly investigated. Chow et al. [39] could show that the pro-apoptotic activity of nilotinib is not restricted to BCR-ABL, c-Kit, or PDGFR-positive cells. Nilotinibinduced apoptosis in cell lines of lymphatic origin was shown to critically rely on activation of caspase-6 and caspase-9 and diVerential expression of Src-kinases [39] . With regard to our results in Ba/F3 T315I cells, originally derived from a murine pro B cell line [40] and showing no or only negligible expression of c-Kit or PDGFR, one could speculate that nilotinib is able to exert BCR-ABL independent pro-apoptotic eVects which are only evident after sensitization by daunorubicin. Furthermore, the possibility of a physically altered interaction between nilotinib and the kinase domain of BCR-ABL after sensitization by standard chemotherapy allowing nilotinib to bind to the mutated T315I target cannot be ruled out either. In a recent report, Tiwari et al. [41] could demonstrate that nilotinib is able to reverse multidrug resistance by inhibiting the activity of ABCB1/Pgp and ABCG2/BCRP/MXR transporters. In one of our previous studies comprising functional rhodamine 123 eZux assays, we could show that imatinib-sensitive LAMA84 cells displayed a lower Pgp activity than imatinib-resistant LAMA84-R cells, whereas K562 exhibited negligible and K562-R cells low Pgp activity [21] . Consequently, in these cell lines the observed synergy between nilotinib and the investigated agents, which with the exception of cytarabine are substrates for the Pgp mediated drug eZux [32] [33] [34] [35] , may be attributed to the inhibition of Pgp by nilotinib.
The drug concentrations applied in our in vitro synergy experiments were primarily selected to enable a reliable analysis according to the Chou and Talalay method, i.e., around the IC50 in vitro. Of course, it is of great relevance, whether these concentrations are also achievable in vivo and the respective synergistic eVects can be expected in a clinical setting. Zhou et al. [42] reported a steady-state C max of 2,160.7 ng/mL (corresponding to 4,081 nM) in CML patients treated with the standard dose of nilotinib 400 mg twice daily. For daunorubicin, depending on the drug formulation varying plasma concentration can be observed. . In 14 patients, who received the standard dose of 100 mg/m 2 etoposide, peak and trough serum concentrations of 18.5 g/mL (31,433 nM) and 0.2 g/mL (340 nM), respectively, could be observed [45] . In patients with relapsed AML or a blast crisis of CML steady-state plasma levels of cytarabine ranged between 7,000 and 24,000 nM after infusion at a dose rate of 250 mg/m 2 per hour for 36-72 h [46] . Thus, with the exception of K562-R and Ba/F3 T315I cells, the concentrations used in our in vitro studies are achievable in a clinical setting (Table 1) .
Nilotinib is approved for imatinib-resistant and -intolerant CML patients in the chronic and accelerated phase of the disease [13, 14] . The newer studies report hematologic and cytogenetic responses to nilotinib in blast crisis, although the response rates are as expected lower [15, 47] . With nilotinib, as a representative of second-generation TKI, displaying synergistic or additive drug interactions with a number of established chemotherapeutics in CML cells, the preclinical data reported in this work support combination treatment regimens for clinical testing. Based on our previous clinical experience with imatinib-based combination treatment in myeloid blast crisis patients [30] , we propose a modern treatment concept for this patient group beginning with an induction treatment with a welltolerated chemotherapy regimen, e.g., mitoxantrone/etoposide (NOVE regimen) given along with nilotinib. Upon response to induction treatment, eligible patients should be assigned to a consolidation with allogeneic stem cell transplantation. Patients not eligible for allogeneic transplantation but Wt enough to receive an intermediate-intensive chemotherapy treatment can be oVered an alternative consolidation with, e.g., intermediate-dose cytarabine combined with nilotinib. After completion of consolidation, a life-long maintenance treatment with nilotinib can be expected to be advantageous for patients not receiving an allogeneic transplant and therefore still harboring a residual CML clone. Regarding the low incidence of CML blast crisis under eYcient imatinib treatment, nowadays a concerted multicenter eVort is needed to implement such a treatment concept in order to yield patient recruitment suYcient for further analysis.
